Skip to content

Lukoye Atwoli

Department of Medicine, Medical College East Africa, and Brain and Mind Institute, Aga Khan University, Nairobi, Kenya.

2 papers in the library · 73 citations · publishing 2025-2026

Papers

Post-traumatic stress disorder: evolving conceptualization and evidence, and future research directions.

World psychiatry : official journal of the World Psychiatric Association (WPA) February 1, 2025 Chris R Brewin, Lukoye Atwoli, Jonathan I Bisson et al. 73 citations

The diagnosis of post-traumatic stress disorder (PTSD) has shaped understanding of trauma responses. Early diagnostic criteria and epidemiological findings, including sociocultural differences, are reviewed. Evidence shows post-traumatic reactions occur in contexts not previously defined as traumatic. Recent developments such as the DSM-5 dissociative subtype and ICD-11 complex PTSD indicate several distinct PTSD phenotypes. Psychological foundations involve disturbances to memory and identity, with a broader focus on identity accommodating group and communal influences. Biological foundations include genetic and neuroimaging studies. While prevention progress has been disappointing, psychological treatments like trauma-focused cognitive behavior therapy, EMDR, and non-trauma-focused therapies are effective. Emerging identity-based approaches and MDMA-assisted psychotherapy show promise. Adapting interventions in resource-limited settings and community-based approaches are priorities.

Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade

The International Journal of Neuropsychopharmacology May 5, 2026 Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar et al.

Between 2013 and 2026, neuropsychopharmacology advanced from stagnation to momentum, producing several first-in-class treatments: rapid-acting drugs for treatment-resistant depression (intranasal esketamine), psychedelic-assisted therapy for PTSD and depression, neuroactive steroid GABA-A receptor positive allosteric modulators (brexanolone, zuranolone) for postpartum depression, non-dopaminergic muscarinic agonists (xanomeline-trospium) for schizophrenia, orexin receptor antagonists for insomnia, and anti-amyloid monoclonal antibodies (lecanemab, donanemab) for early Alzheimer's disease.